Cyclophosphamide

Meningioma

Essen BiotechSmall moleculePhase 2Active

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 48/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the Meningioma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Essen Biotech	Phase 2	B
Anti-Ny Eso-1 Mtcr Pbl National Cancer Institute (NCI)	Phase 2	B
Rvp-001 Reveal Pharmaceuticals Inc.	Phase 2	B
Nivolumab National Cancer Institute (NCI)	Phase 2	B
(S)-(-)-PERILLYL ALCOHOL Neonc Technologies, Inc.	Phase 2	CCC

View all 19 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.